ReviewThe Lancet. Oncology2019
Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
265 papers cite itlatest 60 shown
this paperpooled ittrialcites it